TruScreen Claims Clinical Edge in Cervical Cancer Screening Study

Cervical cancer screening device maker TruScreen Group (ASX/: TRU) has gained fresh clinical backing for its technology, with a newly published peer-reviewed study reporting superior diagnostic performance when its device is paired with high-risk HPV testing.

The independent study, conducted at Panzhihua Central Hospital in China and published in the Journal of Sichuan University, compared TruScreen combined with high-risk human papillomavirus testing (hr-HPV) against the conventional Thinprep cytology test (TCT) paired with HPV testing. The results suggest the TruScreen approach may offer a more accurate alternative to cytology-based screening pathways.

While modest in scale, involving 297 women aged between 21 and 57, the trial provides further clinical validation for the company’s opto-electronic screening technology and its potential role in global cervical cancer detection programs.

Head-to-head comparison with conventional cytology

The trial assessed the effectiveness of two screening combinations in detecting cervical lesions - low-grade squamous intraepithelial lesions (LSIL+) and high-grade lesions (HSIL+), both indicators of potential cervical cancer progression.

Histopathology results from the cohort identified 128 LSIL+ cases and 67 HSIL+ cases, representing 43.1% and 22.6% of the study population respectively.

Against this benchmark, the TruScreen plus hr-HPV combination demonstrated stronger diagnostic metrics than the conventional cytology-based method. Specifically, the study found that:

• TruScreen + hr-HPV delivered a higher area under the ROC curve (AUC), indicating improved overall diagnostic accuracy.

• The combination produced high sensitivity for detecting HSIL+ lesions.

• Specificity and negative predictive value were also superior to the TCT + hr-HPV approach.

In plain English, the technology was more accurate at identifying both true positives and true negatives.

The study authors concluded that the TruScreen co-testing approach “demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test and may serve as an alternative to conventional cytology-based methods in China.”

A growing clinical evidence base

For investors, the study adds another brick to the clinical wall supporting TruScreen’s technology.

The company says its evidence base now comprises more than 30 clinical trials and large-scale studies covering over 40,000 women globally.

The latest results align with the much larger COGA study involving nearly 15,000 women, published in early 2026 in BMC Cancer. That study also concluded that TruScreen outperformed conventional liquid-based cytology and hr-HPV testing when used as a primary screening tool.

Clinical validation is particularly important for medical device companies seeking broader regulatory adoption and integration into national screening programs. In many jurisdictions, health authorities require extensive real-world evidence before recommending new diagnostic technologies.

Why TruScreen’s technology matters

Unlike traditional Pap smears or cytology-based tests, TruScreen’s device uses opto-electronic sensors to analyse cervical tissue in real time.

The handheld device applies low-level electrical and optical stimuli to the cervix and uses AI-enabled algorithms to detect abnormalities instantly. This means results are available at the point of care without requiring tissue samples to be sent to pathology laboratories.

That distinction is significant for countries with limited healthcare infrastructure, where access to cytology labs or trained pathologists can be scarce.

According to executive chairman Tony Ho, the technology is particularly suited to screening initiatives in emerging markets.

“These results continue to support TruScreen’s suitability for integration into cervical cancer screening initiatives globally, particularly in markets where access to pathology infrastructure is limited,” he said.

Strategic tie-up with HPV testing partner

The study also provides additional validation for TruScreen’s partnership with Dalton BioSciences, a Chinese manufacturer of HPV diagnostic kits.

Dalton’s HPV DNA testing products are designed to identify high-risk strains of the virus associated with cervical cancer and can be combined with TruScreen’s device in a co-testing strategy. The arrangement allows TruScreen to distribute HPV in-vitro diagnostic products through its global network.

From a commercial perspective, combining device-based screening with HPV testing potentially expands the company’s addressable market and creates additional revenue streams through consumables and testing kits.

Global footprint steadily expanding

TruScreen markets its flagship device, the TruScreen Ultra, as a primary cervical cancer screening tool that eliminates the need for tissue sampling and laboratory processing.

The device holds regulatory approvals across multiple jurisdictions including Australia, the United Kingdom, China, Saudi Arabia, Mexico and Russia, with ministry-level approvals in countries such as Vietnam and Israel.

Distribution now spans 29 countries, with a manufacturing facility in China established in 2021 to support the local market.

Operational metrics also point to growing utilisation. In the 2024 financial year alone, more than 200,000 examinations were conducted using TruScreen devices worldwide, based on sales of single-use sensors.

The investor lens

For ASX investors, the announcement underscores a familiar theme in medtech - clinical validation precedes commercial adoption.

While a 297-patient study is not transformative on its own, the steady accumulation of peer-reviewed data strengthens the case for broader use of the technology in national screening programs and hospital networks.

If adoption continues to build across emerging healthcare markets where laboratory infrastructure is limited, TruScreen’s real-time screening model could find a receptive audience.

In the meantime, each additional study helps bolster the company’s central claim: that AI-enabled, point-of-care cervical screening may eventually challenge the decades-old cytology status quo.